Research and Development

Showing 15 posts of 9573 posts found.

smart-watch-2845072_640

Wearable tech market set to double to $54 billion by 2023, report says

November 13, 2019 Research and Development, Sales and Marketing pahrma, wearble technology

A new report from GlobalData has revealed that the market for wearable technology in healthcare is expected to more than …
white_and_ford

Abbott CEO to step down after 21 years

November 13, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abbott, appointment

After more than two decades at the head of the company, it has emerged that Miles D White (pictured, right) …
vertex-headquarters

Vertex’s cystic fibrosis portfolio to be made available across Northern Ireland and Wales

November 13, 2019 Research and Development, Sales and Marketing Kalydeco, NHS, Orkambi, Symkevi, Vertex, pharma

After drawn out negotiations and much discontent among cystic fibrosis (CF) patients and their advocates, Vertex has announced that a …
shutterstock_273326141

Mylan and Upjohn merger will create a new entity: Viatris

November 13, 2019 Manufacturing and Production, Research and Development, Sales and Marketing Mylan, Pfizer, Upjohn, Viatris, pharma

The name for the new company emerging out of the merger between Pharma firm Mylan and Pfizer division Upjohn has …

GSK’s Nucala meets Phase 3 goal in reducing hypereosinophilic syndrome flare-ups

November 13, 2019 Research and Development GSK, Nucala, pharma

GlaxoSmithKline has unveiled new Phase 3 data for its IL-5 inhibitor Nucala (mepolizumab), revealing that the therapy met its primary …

Pfizer’s tofacitinib hits main goal in Phase 3 juvenile idiopathic arthritis study

November 12, 2019 Manufacturing and Production, Research and Development Pfizer, pharma, tofacitinib

Pfizer has lifted the lid on new Phase 3 data exploring the efficacy of tofacitinib in the treatment of juvenile …
funk

Lonza CEO to step down in 2020

November 12, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Lonza, appointment

It has been announced that Marc Funk, Chief Executive Officer at Lonza, is set to step down from the role …

Working Life Interview: Alison Muir, Oncology Product Strategy Director at Roche

November 11, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Roche, Working Life, feature, pharma

You studied biology at Liverpool John Moores University before heading straight to GSK in 1990 as a Sales Representative; was …
roche

Roche’s risdiplam hits main goal in spinal muscular atrophy type 2 or 3

November 11, 2019 Research and Development, Sales and Marketing Roche, pharma, risdiplam, spinal muscular atrophy

Roche has lifted the curtain on new data which shows that its investigational survival motor neuron-2 (SMN2) splicing modifier risdiplam …
novartis_window

Novartis reveals strong Phase 2b data for tropifexor in non-alcoholic steatohepatitis

November 11, 2019 Research and Development, Sales and Marketing Novartis, nash, non-alcoholic steatohepatitis, pharma

The latest findings have been revealed from the final stage of Novartis’ Phase 2b evaluation of its non-bile acid FXR …
bavencio

Pfizer and Merck KGaA’s Bavencio falls short of primary endpoint in Phase 3 gastric cancer trial

November 8, 2019 Medical Communications, Research and Development Bavencio, Merck KGaA, Pfizer, pharma

Pfizer and Merck KGaA’s EMD Serono have lifted the lid on new Phase 3 data for Bavencio (avelumab) in the …
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

November 8, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

In our rundown of the week’s most popular stories, President Donald Trump has named his first choice for the top …

Roche terminates Duchenne muscular dystrophy candidate due to poor clinical outlook

November 8, 2019 Medical Communications, Research and Development Duchenne Muscular Dystrophy, Roche, pharma

Roche has revealed its decision to terminate further development of its anti-myostatin adnectin protein agent RG6206 after it became apparent …
astrazeneca_sign_sky

AstraZeneca’s roxadustat boosts haemoglobin levels in two Phase 3 trials

November 8, 2019 Medical Communications, Research and Development AstraZeneca, pharma, roxadustat

AstraZeneca’s hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) roxadustat has made a strong showing in the treatment of deficient haemoglobin (Hb) …

Takeda’s Ninlaro shows progression-free survival benefit in multiple myeloma

November 8, 2019 Medical Communications, Research and Development Ninlaro, Takeda, multiple myeloma, pharma

Takeda has revealed strong new findings for Ninlaro (ixazomib), confirming that the therapy met its primary endpoint as a first-line …
The Gateway to Local Adoption Series

Latest content